Wednesday, April 30, 2008
Amitiza will be marketed by Takeda under license from Sucampo Pharmaceuticals.
SSRIs (namely Pfizer’s Zoloft) is allegedly linked to gender identity disorder. After initiating therapy, some patients feel strong and compelling urges to change sexes. Of course, Zoloft is also linked to homicides (a.k.a., the Christopher Pittman defense).
Bone Disorder Drugs (such as Eli Lilly’s Evista) are linked to Restless Leg Syndrome. But thankfully we have Requip for that. Unfortuantely GSK’s Requip is linked to hallucinations. So, you can live with bone loss or take the cocktail, have shaky legs, and think the aliens are talking to you.
The entire class of estrogen containing HRT products (Wyeth’s Premarin, Vagifem, Femring, FemHRT, etc.) reportedly cause the graying or greening of toenails.
BMS’ old Buspar causes tinnitus. That’s no surprise, it’s in the label. But some patients claim the drug makes them hear voices…in foreign languages.
Thankfully, for those who hear voices, there’s Eli Lilly’s Zyprexa. Unfortunately, Zyprexa reportedly causes the voices to start singing old Neil Diamond songs.
Merck and Schering-Plough’s Zetia produces a strong, uncontrollable cough in a very small number of patients. Most of those patients live in Buffalo, New York, but it’s gotta be the drug’s fault, right?
Remember - all medications carry some risks. If something unusual happens to you, pick up the phone and immediately call a lawyer (even before seeking medical treatment).
This message brought to you by the Association of Trial Lawyers of America (now d.b.a. as the American Association for "Justice").
Tuesday, April 29, 2008
Interestingly, oncologists are one of the few specialties that still read medical journals (probably since the science is changing so significantly). Or rather, still have the time to read journals.
Tuesday, April 15, 2008
This morning, IMS Health announced that the global pharmaceutical market grew just 6.4 percent in 2007, compared to 11.5% back in 2000. Worldwide sales now top $712 billion, compared to $365 billion back in 2000.
Highlights of the IMS Health announcement include:
- U.S., the largest pharmaceutical market (45.9% of total worldwide sales), had sales of $286.5 billion in 2007, but accounted for only a quarter of the growth globally. U.S. growth is an anemic 4.2%
- Latin American sales jumped 11.6% reaching $65.2 billion
- Japan, the second largest market, had growth of only 3.6%
- Europe now registers sales of $221.6 billion, with exception growth coming in Russia at 20.2% and Turkey at 17.2%
- Asian markets experienced significant growth of 13.3%. China grew by 25.7%, Korea at 10.7% and India at 13.0% in 2007
Saturday, April 12, 2008
Takeda has tried for several years to grow its U.S. business organically. The efforts were dismal failure and the company has begun a new strategy of growth by acquisition.
The Millennium acquisition likely makes sense – if Millennium’s pipeline is as robust as they claim it is.
This deal makes more sense than AstraZeneca’s acquisition of MedImmune (see AstraZeneca buys MedImmune, huh?)
Monday, April 7, 2008
It’s a valuable public service (keeping cigarette butts off the ground), while offering smokers a chance to improve their health.
Who says drug companies can’t do good in this world?